Overview

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

Status:
Enrolling by invitation

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This study is a single arm, multi-center phase II study of durvalumab and AZD6738 combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Collaborator:

AstraZeneca

Treatments:

Durvalumab